Therapeutic activity of enviroxime against rhinovirus infection in volunteers - PubMed (original) (raw)

Clinical Trial

Therapeutic activity of enviroxime against rhinovirus infection in volunteers

R J Phillpotts et al. Antimicrob Agents Chemother. 1983 May.

Abstract

The therapeutic effect of intranasal 2-amino-1-(isopropylsulphonyl)-6-benzimidazole phenyl ketone oxime (enviroxime) against human rhinovirus type 9 was evaluated in a double-blind, placebo-controlled volunteer trial. Enviroxime given 6 times a day was well tolerated, producing a reduction in clinical evidence of infection which coincided with the start of medication (44 h after virus challenge). Although there was a statistically significant reduction in clinical score in the enviroxime group on day 5 after virus challenge, reductions in total clinical score accumulated during the trial and reductions in the quantity of nasal secretions were not significant. A separate analysis was performed on data from volunteers who did not have symptoms when medication began (and who might have been expected to benefit more from enviroxime therapy). No apparent enhancement of the effects of enviroxime could be demonstrated in this group.

PubMed Disclaimer

Cited by

From the "One-Molecule, One-Target, One-Disease" Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) Infections.
Roux H, Touret F, Rathelot P, Vanelle P, Roche M. Roux H, et al. Pharmaceuticals (Basel). 2024 Sep 16;17(9):1218. doi: 10.3390/ph17091218. Pharmaceuticals (Basel). 2024. PMID: 39338380 Free PMC article. Review.
A Plethora of Functions Condensed into Tiny Phospholipids: The Story of PI4P and PI(4,5)P2.
Bura A, Čabrijan S, Đurić I, Bruketa T, Jurak Begonja A. Bura A, et al. Cells. 2023 May 17;12(10):1411. doi: 10.3390/cells12101411. Cells. 2023. PMID: 37408244 Free PMC article. Review.
Beyond PI3Ks: targeting phosphoinositide kinases in disease.
Burke JE, Triscott J, Emerling BM, Hammond GRV. Burke JE, et al. Nat Rev Drug Discov. 2023 May;22(5):357-386. doi: 10.1038/s41573-022-00582-5. Epub 2022 Nov 14. Nat Rev Drug Discov. 2023. PMID: 36376561 Free PMC article. Review.
Therapeutics for fulminant hepatitis caused by enteroviruses in neonates.
Wang LC, Tsai HP, Chen SH, Wang SM. Wang LC, et al. Front Pharmacol. 2022 Oct 20;13:1014823. doi: 10.3389/fphar.2022.1014823. eCollection 2022. Front Pharmacol. 2022. PMID: 36339581 Free PMC article. Review.
Enterovirus Replication Organelles and Inhibitors of Their Formation.
Li X, Wang M, Cheng A, Wen X, Ou X, Mao S, Gao Q, Sun D, Jia R, Yang Q, Wu Y, Zhu D, Zhao X, Chen S, Liu M, Zhang S, Liu Y, Yu Y, Zhang L, Tian B, Pan L, Chen X. Li X, et al. Front Microbiol. 2020 Aug 20;11:1817. doi: 10.3389/fmicb.2020.01817. eCollection 2020. Front Microbiol. 2020. PMID: 32973693 Free PMC article. Review.

Therapeutic activity of enviroxime against rhinovirus infection in volunteers - PubMed (original) (raw)